866-997-4948(US-Canada Toll Free)

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 48 Pages

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Review, H2 2016, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.

Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea and abdominal pain. Predisposing factors include weakened immune systems, burns and surgical wounds.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview 7
Pipeline Products for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis 8
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Development by Companies 9
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics under Investigation by Universities/Institutes 10
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Development by Companies 13
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Products under Investigation by Universities/Institutes 14
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development 15
Arsanis, Inc. 15
ContraFect Corporation 16
Debiopharm International SA 17
Sealife PHARMA GMBH 18
Sumitomo Dainippon Pharma Co Ltd 19
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ASN-100 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CF-301 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Debio-1450 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
NAI-108 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
SLP-0904 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
SLP-0905 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
SM-295291 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SM-369926 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules for Bacterial Infections - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
targocil - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects 44
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products 45
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones 46
Featured News & Press Releases 46
Dec 02, 2014: ContraFect Submits Complete Response to IND Clinical Hold for CF-301 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Arsanis, Inc., H2 2016 15
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by ContraFect Corporation, H2 2016 16
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA , H2 2016 17
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 18
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 19
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Stage and Target, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 28
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2016 44
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2016 45

List of Figures
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2016 7
Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 20
Number of Products by Targets, H2 2016 21
Number of Products by Stage and Targets, H2 2016 21
Number of Products by Mechanism of Actions, H2 2016 23
Number of Products by Stage and Mechanism of Actions, H2 2016 23
Number of Products by Routes of Administration, H2 2016 25
Number of Products by Stage and Routes of Administration, H2 2016 25
Number of Products by Molecule Types, H2 2016 27
Number of Products by Stage and Top 10 Molecule Types, H2 2016 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *